Telesis Bio Company Overview
About Telesis Bio
Telesis Bio (NASDAQ:TBIO) operates in the biotechnology sector, focusing on leveraging synthetic biology to innovate in healthcare and environmental solutions. This dynamic company specializes in developing cutting-edge tools and techniques for genetic engineering and manipulation, aiming to address some of the most pressing challenges in medicine and sustainability. Telesis Bio's projects range from therapeutic discovery and development to sustainable bio-manufactured products, indicating a broad and ambitious agenda. The company's primary objectives include advancing healthcare options through novel treatments and contributing to global sustainability efforts by exploring new ways to produce food and energy more efficiently. By pushing the boundaries of synthetic biology, Telesis Bio seeks to create substantial value for its stakeholders and make significant contributions to society.
Snapshot
Operations
Products and/or services of Telesis Bio
- Development of precision biosynthesis platforms for efficient and sustainable production of chemicals and fuels.
- Design of synthetic biology tools for genome editing across various organisms.
- Creation of advanced bioinformatics solutions to enhance genetic engineering processes.
- Manufacture of microfluidics-based devices for high-throughput screening and analysis.
- Provision of custom DNA synthesis services for research and development purposes.
- Offering of consulting services in bioengineering, process optimization, and regulatory compliance.
Telesis Bio executive team
- Mr. Eric EsserPresident, CEO, COO & Chairman
- Mr. Robert H. CutlerChief Legal Officer
- Mr. William J. KullbackChief Financial Officer
- Mr. Daniel G. Gibson Ph.D.Chief Technology Officer
- Ms. Jen CarrollVice President of Investor Relations
- Mr. Decky Goodrich M.B.A.Senior Vice President of Corporate Development
- Richard LepkeDirector of Investor Relations